ANTX Insider Transactions
| Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2024-03-15 | Eckburg Paul | officer: Chief Medical Officer | 51,416 | A-Award | A | 30,000 | 0.00 | 0.00 |
| 2024-03-15 | Day Lucy | officer: Chief Financial Officer | 55,000 | A-Award | A | 55,000 | 3.00 | 165,000.00 |
| 2024-03-15 | Day Lucy | officer: Chief Financial Officer | 30,627 | A-Award | A | 27,500 | 0.00 | 0.00 |
| 2024-03-15 | Eizen Joshua M | officer: Chief Legal Officer | 60,000 | A-Award | A | 60,000 | 3.00 | 180,000.00 |
| 2024-03-15 | Eizen Joshua M | officer: Chief Legal Officer | 32,447 | A-Award | A | 30,000 | 0.00 | 0.00 |
| 2024-03-15 | Krause Kevin Michael | officer: Chief Strategy Officer | 60,000 | A-Award | A | 60,000 | 3.00 | 180,000.00 |
| 2024-03-15 | Krause Kevin Michael | officer: Chief Strategy Officer | 31,914 | A-Award | A | 30,000 | 0.00 | 0.00 |
| 2024-03-15 | Chanda Sanjay | officer: Chief Development Officer | 55,000 | A-Award | A | 55,000 | 3.00 | 165,000.00 |
| 2024-03-15 | Chanda Sanjay | officer: Chief Development Officer | 28,235 | A-Award | A | 27,500 | 0.00 | 0.00 |
| 2024-03-15 | Eckburg Paul | officer: Chief Medical Officer | 60,000 | A-Award | A | 60,000 | 3.00 | 180,000.00 |
| 2024-03-15 | Eckburg Paul | officer: Chief Medical Officer | 51,416 | A-Award | A | 30,000 | 0.00 | 0.00 |
| 2024-03-15 | Easom Eric | director, officer: Chief Executive Officer | 198,000 | A-Award | A | 198,000 | 3.00 | 594,000.00 |
| 2024-03-15 | Easom Eric | director, officer: Chief Executive Officer | 101,130 | A-Award | A | 99,000 | 0.00 | 0.00 |
| 2024-01-18 | Zakrzewski Joseph S | director | 405,880 | S-Sale | D | 100,000 | 19.11 | 1,911,410.00 |
| 2024-01-16 | Aziz Kabeer | director | 1,995,958 | S-Sale | D | 84,093 | 19.65 | 1,652,427.00 |
| 2024-01-16 | Aziz Kabeer | director | 377,542 | S-Sale | D | 15,907 | 19.65 | 312,573.00 |
| 2024-01-16 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 1,995,958 | S-Sale | D | 84,093 | 19.65 | 1,652,427.00 |
| 2024-01-16 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 377,542 | S-Sale | D | 15,907 | 19.65 | 312,573.00 |
| 2024-01-12 | Readnour Robin Shane | director | 485,073 | S-Sale | D | 719 | 21.91 | 15,753.00 |
| 2024-01-12 | Readnour Robin Shane | director | 414,788 | S-Sale | D | 706 | 21.92 | 15,476.00 |
| 2024-01-10 | Readnour Robin Shane | director | 485,792 | S-Sale | D | 1,800 | 21.92 | 39,456.00 |
| 2024-01-10 | Readnour Robin Shane | director | 415,494 | S-Sale | D | 1,869 | 21.93 | 40,987.00 |
| 2024-01-09 | Krause Kevin Michael | officer: Chief Strategy Officer | 49,868 | M-Exempt | D | 2,417 | 0.42 | 1,015.00 |
| 2024-01-09 | Krause Kevin Michael | officer: Chief Strategy Officer | 26,832 | M-Exempt | D | 5,000 | 6.60 | 33,000.00 |
| 2024-01-09 | Krause Kevin Michael | officer: Chief Strategy Officer | 9,331 | M-Exempt | A | 5,000 | 6.60 | 33,000.00 |
| 2024-01-09 | Krause Kevin Michael | officer: Chief Strategy Officer | 4,331 | M-Exempt | A | 2,417 | 0.42 | 1,015.00 |
| 2024-01-09 | Krause Kevin Michael | officer: Chief Strategy Officer | 1,914 | S-Sale | D | 7,417 | 20.14 | 149,367.00 |
| 2024-01-02 | Krause Kevin Michael | officer: Chief Strategy Officer | 52,285 | M-Exempt | D | 2,583 | 0.42 | 1,085.00 |
| 2024-01-02 | Krause Kevin Michael | officer: Chief Strategy Officer | 4,497 | M-Exempt | A | 2,583 | 0.42 | 1,085.00 |
| 2024-01-02 | Krause Kevin Michael | officer: Chief Strategy Officer | 1,914 | S-Sale | D | 2,583 | 20.12 | 51,967.00 |
| 2024-01-02 | Easom Eric | director, officer: Chief Executive Officer | 2,130 | S-Sale | D | 2,777 | 20.09 | 55,802.00 |
| 2023-11-14 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 2,080,051 | S-Sale | D | 1,522 | 16.15 | 24,574.00 |
| 2023-11-14 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 393,449 | S-Sale | D | 288 | 16.15 | 4,650.00 |
| 2023-11-14 | Aziz Kabeer | director, 10 percent owner: | 2,080,051 | S-Sale | D | 1,522 | 16.15 | 24,574.00 |
| 2023-11-14 | Aziz Kabeer | director, 10 percent owner: | 393,449 | S-Sale | D | 288 | 16.15 | 4,650.00 |
| 2023-09-29 | Aziz Kabeer | director, 10 percent owner: | 2,086,343 | S-Sale | D | 83,337 | 16.28 | 1,356,726.00 |
| 2023-10-02 | Aziz Kabeer | director, 10 percent owner: | 2,081,573 | S-Sale | D | 4,770 | 16.07 | 76,654.00 |
| 2023-09-29 | Aziz Kabeer | director, 10 percent owner: | 394,639 | S-Sale | D | 15,764 | 16.28 | 256,638.00 |
| 2023-10-02 | Aziz Kabeer | director, 10 percent owner: | 393,737 | S-Sale | D | 902 | 16.07 | 14,495.00 |
| 2023-09-29 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 2,086,343 | S-Sale | D | 83,337 | 16.28 | 1,356,726.00 |
| 2023-10-02 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 2,081,573 | S-Sale | D | 4,770 | 16.07 | 76,654.00 |
| 2023-09-29 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 394,639 | S-Sale | D | 15,764 | 16.28 | 256,638.00 |
| 2023-10-02 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 393,737 | S-Sale | D | 902 | 16.07 | 14,495.00 |
| 2023-09-27 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 2,176,840 | S-Sale | D | 707 | 16.07 | 11,361.00 |
| 2023-09-28 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 2,169,680 | S-Sale | D | 7,160 | 16.11 | 115,348.00 |
| 2023-09-27 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 411,759 | S-Sale | D | 134 | 16.07 | 2,153.00 |
| 2023-09-28 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 410,403 | S-Sale | D | 1,356 | 16.11 | 21,845.00 |
| 2023-09-27 | Aziz Kabeer | director, 10 percent owner: | 2,176,840 | S-Sale | D | 707 | 16.07 | 11,361.00 |
| 2023-09-28 | Aziz Kabeer | director, 10 percent owner: | 2,169,680 | S-Sale | D | 7,160 | 16.11 | 115,348.00 |
| 2023-09-27 | Aziz Kabeer | director, 10 percent owner: | 411,759 | S-Sale | D | 134 | 16.07 | 2,153.00 |
| 2023-09-28 | Aziz Kabeer | director, 10 percent owner: | 410,403 | S-Sale | D | 1,356 | 16.11 | 21,845.00 |
| 2023-09-13 | Aziz Kabeer | director, 10 percent owner: | 2,177,547 | S-Sale | D | 336 | 16.00 | 5,376.00 |
| 2023-09-13 | Aziz Kabeer | director, 10 percent owner: | 411,893 | S-Sale | D | 64 | 16.00 | 1,024.00 |
| 2023-09-13 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 2,177,547 | S-Sale | D | 336 | 16.00 | 5,376.00 |
| 2023-09-13 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 411,893 | S-Sale | D | 64 | 16.00 | 1,024.00 |
| 2023-09-06 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 2,180,724 | S-Sale | D | 3,164 | 16.02 | 50,687.00 |
| 2023-09-07 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 2,177,883 | S-Sale | D | 2,841 | 16.05 | 45,598.00 |
| 2023-09-06 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 412,494 | S-Sale | D | 598 | 16.02 | 9,580.00 |
| 2023-09-07 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 411,957 | S-Sale | D | 537 | 16.05 | 8,619.00 |
| 2023-09-06 | Aziz Kabeer | director, 10 percent owner: | 2,180,724 | S-Sale | D | 3,164 | 16.02 | 50,687.00 |
| 2023-09-07 | Aziz Kabeer | director, 10 percent owner: | 2,177,883 | S-Sale | D | 2,841 | 16.05 | 45,598.00 |
| 2023-09-06 | Aziz Kabeer | director, 10 percent owner: | 412,494 | S-Sale | D | 598 | 16.02 | 9,580.00 |
| 2023-09-07 | Aziz Kabeer | director, 10 percent owner: | 411,957 | S-Sale | D | 537 | 16.05 | 8,619.00 |
| 2023-08-23 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 2,183,888 | S-Sale | D | 336 | 16.00 | 5,376.00 |
| 2023-08-23 | Adjuvant Global Health Technology Fund, L.P. | 10 percent owner | 413,092 | S-Sale | D | 64 | 16.00 | 1,024.00 |
| 2023-08-23 | Aziz Kabeer | director, 10 percent owner: | 2,183,888 | S-Sale | D | 336 | 16.00 | 5,376.00 |
| 2023-08-23 | Aziz Kabeer | director, 10 percent owner: | 413,092 | S-Sale | D | 64 | 16.00 | 1,024.00 |
| 2023-08-18 | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 5,135,683 | P-Purchase | A | 1,777,778 | 9.00 | 16,000,002.00 |
| 2023-06-07 | Aziz Kabeer | director, 10 percent owner: | 23,742 | A-Award | A | 23,742 | 5.91 | 140,315.00 |
| 2023-06-07 | Zakrzewski Joseph S | director | 23,742 | A-Award | A | 23,742 | 5.91 | 140,315.00 |
| 2023-06-07 | FitzPatrick Margaret M | director | 23,742 | A-Award | A | 23,742 | 5.91 | 140,315.00 |
| 2023-06-07 | Wong Stephanie | director | 23,742 | A-Award | A | 23,742 | 5.91 | 140,315.00 |
| 2023-06-07 | Marks Gilbert Lynn | director | 23,742 | A-Award | A | 23,742 | 5.91 | 140,315.00 |
| 2023-06-07 | Martin Patricia A. | director | 23,742 | A-Award | A | 23,742 | 5.91 | 140,315.00 |
| 2023-06-07 | Spigelman Melvin K | director | 23,742 | A-Award | A | 23,742 | 5.91 | 140,315.00 |
| 2023-06-07 | Readnour Robin Shane | director | 23,742 | A-Award | A | 23,742 | 5.91 | 140,315.00 |
| 2023-05-15 | Easom Eric | director, officer: Chief Executive Officer | 1,015,766 | P-Purchase | A | 10,000 | 5.38 | 53,770.00 |
| 2023-02-23 | Easom Eric | director, officer: Chief Executive Officer | 267,650 | A-Award | A | 267,650 | 11.99 | 3,209,124.00 |
| 2023-02-15 | Day Lucy | officer: Chief Financial Officer | 82,300 | A-Award | A | 82,300 | 14.29 | 1,176,067.00 |
| 2023-02-15 | Chanda Sanjay | officer: Chief Development Officer | 57,950 | A-Award | A | 57,950 | 14.29 | 828,106.00 |
| 2023-02-15 | Eckburg Paul | officer: Chief Medical Officer | 70,950 | A-Award | A | 70,950 | 14.29 | 1,013,875.00 |
| 2023-02-15 | Eizen Joshua M | officer: Chief Legal Officer | 50,150 | A-Award | A | 50,150 | 14.29 | 716,644.00 |
| 2023-02-15 | Nazak Michael Adrian | officer: Chief Accounting Officer | 16,600 | A-Award | A | 16,600 | 14.29 | 237,214.00 |
| 2023-02-15 | Krause Kevin Michael | officer: Chief Strategy Officer | 62,200 | A-Award | A | 62,200 | 14.29 | 888,838.00 |
| 2022-11-10 | Easom Eric | officer: Chief Executive Officer | 4,930 | S-Sale | D | 4,413 | 15.32 | 67,628.00 |
| 2022-11-14 | Easom Eric | officer: Chief Executive Officer | 4,907 | S-Sale | D | 23 | 15.04 | 345.90 |
| 2022-11-08 | Easom Eric | officer: Chief Executive Officer | 16,273 | S-Sale | D | 5,800 | 15.41 | 89,388.00 |
| 2022-11-08 | Easom Eric | officer: Chief Executive Officer | 15,018 | S-Sale | D | 1,255 | 16.38 | 20,559.00 |
| 2022-11-09 | Easom Eric | officer: Chief Executive Officer | 4,907 | S-Sale | D | 10,111 | 15.61 | 157,847.00 |
| 2022-11-03 | Easom Eric | officer: Chief Executive Officer | 29,021 | S-Sale | D | 11,082 | 15.67 | 173,683.00 |
| 2022-11-03 | Easom Eric | officer: Chief Executive Officer | 25,938 | S-Sale | D | 3,083 | 16.02 | 49,376.00 |
| 2022-11-04 | Easom Eric | officer: Chief Executive Officer | 17,110 | S-Sale | D | 8,828 | 15.80 | 139,474.00 |
| 2022-11-07 | Easom Eric | officer: Chief Executive Officer | 6,943 | S-Sale | D | 10,167 | 15.90 | 161,705.00 |
| 2022-11-07 | Easom Eric | officer: Chief Executive Officer | 4,907 | S-Sale | D | 2,036 | 16.72 | 34,036.00 |
| 2022-10-31 | Easom Eric | officer: Chief Executive Officer | 6,451 | S-Sale | D | 2,688 | 15.39 | 41,363.00 |
| 2022-11-02 | Easom Eric | officer: Chief Executive Officer | 4,907 | S-Sale | D | 1,544 | 15.07 | 23,263.00 |
| 2022-10-27 | Easom Eric | officer: Chief Executive Officer | 6,590 | S-Sale | D | 924 | 15.36 | 14,190.00 |
| 2022-10-28 | Easom Eric | officer: Chief Executive Officer | 4,907 | S-Sale | D | 1,683 | 15.09 | 25,392.00 |
| 2022-10-14 | Eizen Joshua M | officer: Chief Legal Officer | 92,000 | A-Award | A | 92,000 | 0.00 | 0.00 |
| 2022-10-24 | Easom Eric | officer: Chief Executive Officer | 11,391 | S-Sale | D | 2,866 | 16.17 | 46,344.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
